The	DT	2
limits	NNS	6
to	TO	2
legal	JJ	5
absurdity	NN	3
stretched	VBD	0
another	DT	8
notch	NN	6
this	DT	10
week	NN	6
when	WRB	6
the	DT	14
Supreme	NNP	14
Court	NNP	15
refused	VBD	11
to	TO	17
hear	VB	15
an	DT	19
appeal	NN	17
from	IN	19
a	DT	22
case	NN	20
that	WDT	22
says	VBZ	23
corporate	JJ	26
defendants	NNS	27
must	MD	24
pay	VB	27
damages	NNS	28
even	RB	31
after	IN	28
proving	VBG	31
that	IN	32
they	PRP	35
could	MD	33
not	RB	35
possibly	RB	35
have	VB	35
caused	VBN	38
the	DT	41
harm	NN	39
.	.	6

We	PRP	2
can	MD	0
understand	VB	2
and	CC	3
share	VB	3
the	DT	7
compassion	NN	3
that	WDT	7
makes	VBZ	8
judges	NNS	12
sometimes	RB	12
wish	VB	9
to	TO	14
offer	VB	12
a	DT	16
kind	NN	14
of	IN	16
Solomonic	JJ	19
aid	NN	17
to	TO	14
those	DT	20
who	WP	21
've	VBP	22
been	VBN	23
hurt	VBN	24
.	.	2

But	CC	4
this	DT	3
case	NN	4
is	VBZ	0
a	DT	7
stark	JJ	7
lesson	NN	4
in	IN	7
how	WRB	8
the	DT	11
failures	NNS	17
of	IN	11
the	DT	16
traditional	JJ	16
policy-making	JJ	16
process	NN	12
have	VBP	9
left	VBN	17
the	DT	20
courts	NNS	18
as	IN	18
the	DT	24
only	JJ	24
forum	NN	21
this	DT	26
country	NN	27
has	VBZ	24
to	TO	29
debate	VB	24
risk	NN	34
,	,	34
technology	NN	34
and	CC	34
innovation	NN	29
.	.	4

Too	RB	9
often	RB	1
now	RB	9
,	,	9
a	DT	8
single	JJ	8
court	NN	8
decision	NN	9
becomes	VBZ	0
the	DT	11
precedent	NN	9
for	IN	11
other	JJ	17
,	,	17
less	RBR	16
compelling	JJ	17
cases	NNS	12
.	.	9

From	IN	11
the	DT	3
1940s	CD	1
until	IN	1
1971	CD	4
,	,	11
some	DT	10
two	CD	7
million	CD	7
women	NNS	11
took	VBD	0
the	DT	15
synthetic	JJ	15
hormone	NN	15
diethylstilbestrol	NN	11
-LRB-	-LRB-	17
DES	NNP	15
-RRB-	-RRB-	17
to	TO	20
prevent	VB	11
miscarriages	NNS	24
and	CC	24
morning	NN	24
sickness	NN	20
.	.	11

The	DT	2
drug	NN	3
was	VBD	0
approved	VBN	3
by	IN	4
the	DT	10
Food	NNP	10
and	CC	10
Drug	NNP	10
Administration	NNP	5
and	CC	4
marketed	VBN	4
by	IN	12
some	DT	17
300	CD	14
pharmaceutical	JJ	17
companies	NNS	13
,	,	12
often	RB	20
under	IN	12
generic	JJ	22
labels	NNS	20
.	.	3

In	IN	6
the	DT	3
1970s	CD	1
,	,	6
scientists	NNS	6
reported	VBD	0
cancer	NN	8
cases	NNS	6
among	IN	8
the	DT	11
daughters	NNS	9
of	IN	11
DES	NNP	14
users	NNS	12
.	.	6

The	DT	2
cases	NNS	4
quickly	RB	4
went	VBD	16
to	TO	4
court	NN	5
,	,	16
but	CC	16
the	DT	10
mothers	NNS	16
of	IN	10
several	JJ	15
thousand	CD	15
DES	NNP	15
plaintiffs	NNS	11
could	MD	0
n't	RB	16
recall	VB	16
whose	WP$	18
brand	NN	19
they	PRP	22
used	VBD	19
.	.	16

Beginning	VBG	14
in	IN	1
1980	CD	2
,	,	14
courts	NNS	14
in	IN	5
several	JJ	8
states	NNS	6
including	VBG	8
California	NNP	13
and	CC	13
New	NNP	13
York	NNP	9
decided	VBD	0
to	TO	16
suspend	VB	14
the	DT	19
common-law	NN	19
rule	NN	16
that	IN	19
plaintiffs	NNS	22
must	MD	20
prove	VB	22
that	IN	23
the	DT	26
defendants	NNS	27
are	VBP	24
the	DT	29
ones	NNS	27
who	WP	29
are	VBP	30
liable	JJ	31
.	.	14

Courts	NNS	2
made	VBD	0
the	DT	4
assumption	NN	2
that	IN	4
all	DT	8
DES	NNP	8
pills	NNS	9
were	VBD	5
essentially	RB	9
the	DT	12
same	JJ	9
,	,	2
and	CC	2
created	VBD	2
a	DT	18
market-share	JJ	18
test	NN	15
so	IN	20
that	IN	15
damages	NNS	22
would	MD	20
be	VB	22
assessed	VBN	23
against	IN	24
drug	NN	27
makers	NNS	25
in	IN	24
the	DT	30
proportion	NN	28
of	IN	30
their	PRP$	33
share	NN	31
of	IN	33
the	DT	37
original	JJ	37
sales	NNS	34
.	.	2

This	DT	2
has	VBZ	0
some	DT	4
logic	NN	2
.	.	2

Drug	NN	2
makers	NNS	3
should	MD	0
n't	RB	3
be	VB	3
able	JJ	5
to	TO	8
duck	VB	6
liability	NN	8
because	IN	8
people	NNS	12
could	MD	10
n't	RB	12
identify	VB	12
precisely	RB	14
which	WDT	14
identical	JJ	16
drug	NN	16
was	VBD	16
used	VBN	19
.	.	3

But	CC	4
courts	NNS	4
quickly	RB	4
tumbled	VBD	0
down	IN	4
a	DT	8
slippery	JJ	8
slope	NN	5
.	.	4

Just	RB	2
as	IN	10
all	DT	4
plaintiffs	NNS	5
are	VBP	2
not	RB	5
alike	RB	5
,	,	10
it	PRP	10
turns	VBZ	0
out	RP	10
that	IN	10
DES	NNP	14
defendants	NNS	15
marketed	VBD	12
the	DT	17
drugs	NNS	15
differently	RB	15
and	CC	15
may	MD	15
have	VB	20
offered	VBN	21
different	JJ	24
warranties	NNS	22
.	.	10

The	DT	3
ultimate	JJ	3
result	NN	4
came	VBD	0
in	IN	4
Hymowitz	NNP	8
v.	CC	8
Lilly	NNP	5
,	,	8
where	WRB	8
the	DT	15
highest	JJS	15
New	NNP	15
York	NNP	15
court	NN	16
expanded	VBD	10
the	DT	19
market-share	JJ	19
approach	NN	16
for	IN	16
the	DT	23
first	JJ	23
time	NN	20
to	TO	25
say	VB	16
that	IN	25
drug	NN	28
makers	NNS	41
that	WDT	28
could	MD	29
prove	VB	30
Mindy	NNP	34
Hymowitz	NNP	34
's	POS	35
mother	NN	36
did	VBD	31
n't	RB	36
use	VB	36
their	PRP$	40
pill	NN	38
must	MD	26
still	RB	41
pay	VB	41
their	PRP$	45
share	NN	43
of	IN	45
any	DT	48
damages	NNS	46
.	.	4

But	CC	17
as	IN	17
Duke	NNP	9
University	NNP	9
law	NN	9
professor	NN	9
William	NNP	9
Van	NNP	9
Alstyne	NNP	10
notes	VBZ	2
,	,	17
by	IN	17
this	DT	14
reasoning	NN	12
a	DT	16
defendant	NN	17
could	MD	0
be	VB	17
held	VBN	18
liable	JJ	19
in	IN	19
New	NNP	23
York	NNP	21
for	IN	19
a	DT	27
bad	JJ	27
apple	NN	24
even	RB	29
if	IN	19
he	PRP	31
sold	VBD	29
all	PDT	34
his	PRP$	34
apples	NNS	31
in	IN	31
California	NNP	35
.	.	17

Despite	IN	13
the	DT	5
Supreme	NNP	5
Court	NNP	5
's	POS	6
refusal	NN	1
to	TO	8
hear	VB	6
the	DT	10
case	NN	8
,	,	13
there	EX	13
are	VBP	0
serious	JJ	16
constitutional	JJ	16
issues	NNS	13
of	IN	16
due	JJ	19
process	NN	22
and	CC	22
uncompensated	JJ	22
takings	NNS	17
from	IN	22
the	DT	25
defendants	NNS	23
.	.	13

The	DT	3
big	JJ	3
problem	NN	7
,	,	7
however	RB	7
,	,	7
is	VBZ	0
that	IN	7
there	EX	10
's	VBZ	8
no	DT	12
guarantee	NN	10
that	IN	12
this	DT	15
reasoning	NN	16
will	MD	13
be	VB	16
limited	VBN	17
to	TO	18
DES	NNP	19
or	CC	19
to	TO	19
drugs	NNS	22
.	.	7

The	DT	2
problem	NN	4
here	RB	4
goes	VBZ	0
well	RB	6
beyond	IN	4
twisting	VBG	6
legal	JJ	9
doctrine	NN	7
.	.	4

The	DT	4
California	NNP	4
Supreme	NNP	4
Court	NNP	7
last	JJ	6
year	NN	7
reversed	VBD	0
direction	NN	7
to	TO	10
make	VB	7
it	PRP	15
much	RB	13
harder	JJR	15
to	TO	15
win	VB	10
DES	NNP	17
cases	NNS	15
because	IN	7
the	DT	20
justices	NNS	21
saw	VBD	18
how	WRB	21
all	PDT	26
the	DT	26
pharmaceutical	JJ	26
litigation	NN	27
has	VBZ	22
chilled	VBN	27
the	DT	30
introduction	NN	28
of	IN	30
new	JJ	33
drugs	NNS	31
.	.	7

The	DT	2
court	NN	3
rejected	VBD	0
strict	JJ	5
liability	NN	3
for	IN	5
prescription	NN	8
drugs	NNS	6
,	,	3
citing	VBG	3
the	DT	16
huge	JJ	16
,	,	16
hidden	VBN	16
social	JJ	16
costs	NNS	10
.	.	3

``	``	42
Public	JJ	3
policy	NN	4
favors	VBZ	42
the	DT	8
development	NN	8
and	CC	8
marketing	NN	4
of	IN	8
beneficial	JJ	12
new	JJ	12
drugs	NNS	9
,	,	4
even	RB	15
though	IN	4
some	DT	17
risks	NNS	21
,	,	21
perhaps	RB	21
serious	JJ	21
ones	NNS	23
,	,	21
might	MD	15
accompany	VB	23
their	PRP$	26
introduction	NN	24
because	IN	4
drugs	NNS	29
can	MD	27
save	VB	29
lives	NNS	30
and	CC	30
reduce	VB	30
pain	NN	36
and	CC	36
suffering	NN	33
,	,	42
''	''	42
the	DT	41
unanimous	JJ	41
court	NN	42
said	VBD	0
.	.	42

The	DT	3
California	NNP	3
justices	NNS	4
noted	VBD	0
that	IN	4
the	DT	7
fear	NN	11
of	IN	7
litigation	NN	8
already	RB	11
forced	VBD	5
the	DT	16
only	JJ	16
remaining	VBG	16
anti-morning-sickness	JJ	16
drug	NN	18
,	,	18
Bendectin	NNP	11
,	,	18
off	IN	11
the	DT	23
U.S.	NNP	23
market	NN	20
.	.	4

This	DT	2
raises	VBZ	0
the	DT	5
key	JJ	5
issue	NN	2
:	:	5
What	WP	5
to	TO	9
do	VB	7
about	IN	9
people	NNS	10
who	WP	11
suffer	VBP	12
serious	JJ	15
injuries	NNS	13
from	IN	15
beneficial	JJ	18
drugs	NNS	16
?	.	2

We	PRP	3
now	RB	3
know	VBP	0
that	IN	3
holding	VBG	24
drug	NN	7
makers	NNS	8
liable	JJ	5
where	WRB	5
there	EX	11
's	VBZ	9
no	DT	13
evidence	NN	11
that	IN	13
they	PRP	17
or	CC	17
anyone	NN	19
else	RB	17
knew	VBD	14
of	IN	19
any	DT	22
risks	NNS	20
only	RB	24
means	VBZ	4
the	DT	26
drugs	NNS	27
wo	MD	24
n't	RB	27
be	VB	27
available	JJ	29
to	TO	30
anyone	NN	31
.	.	3

As	IN	24
liability	NN	5
expert	NN	5
Peter	NNP	5
Huber	NNP	6
tells	VBZ	1
us	PRP	6
,	,	24
after	IN	24
the	DT	12
Hymowitz	NNP	12
case	NN	9
,	,	24
if	IN	24
any	DT	17
drug	NN	17
maker	NN	18
introduces	VBZ	14
an	DT	21
anti-miscarriage	JJ	21
drug	NN	18
``	``	24
it	PRP	24
's	VBZ	0
time	NN	24
to	TO	27
sell	VB	25
that	DT	30
company	NN	30
's	POS	31
stock	NN	27
short	RB	27
.	.	24
''	''	24

We	PRP	3
also	RB	3
know	VBP	30
that	IN	3
the	DT	7
tort	NN	7
system	NN	8
is	VBZ	4
a	DT	11
lousy	JJ	11
way	NN	8
to	TO	13
compensate	VB	11
victims	NNS	13
anyway	RB	8
;	:	30
some	DT	18
win	VBP	30
the	DT	21
legal	JJ	21
lottery	NN	18
,	,	30
others	NNS	24
get	VBP	30
much	RB	26
less	JJR	24
and	CC	30
contingency-fee	JJ	29
lawyers	NNS	30
take	VBP	0
a	DT	33
big	JJ	33
cut	NN	30
either	DT	35
way	NN	30
.	.	30

DES	NNP	2
daughters	NNS	5
and	CC	5
other	JJ	5
victims	NNS	8
of	IN	5
drugs	NNS	6
would	MD	0
be	VB	8
better	JJR	9
off	IN	10
if	IN	9
their	PRP$	14
cases	NNS	15
were	VBD	12
taken	VBN	15
out	IN	16
of	IN	17
the	DT	20
courts	NNS	18
.	.	8

Congress	NNP	2
could	MD	0
create	VB	2
a	DT	6
compensation	NN	6
program	NN	3
to	TO	8
help	VB	6
such	JJ	10
victims	NNS	8
while	IN	8
protecting	VBG	11
the	DT	15
national	JJ	15
interest	NN	12
in	IN	15
encouraging	VBG	16
new	JJ	19
drugs	NNS	17
.	.	2

But	CC	17
a	DT	4
1986	CD	4
law	NN	17
that	WDT	4
supposedly	RB	7
replaced	VBD	5
lawsuits	NNS	7
over	IN	8
children	NNS	11
's	POS	12
vaccines	NNS	9
with	IN	7
a	DT	16
compensation	NN	16
fund	NN	13
has	VBZ	0
predictably	RB	17
led	VBN	17
to	TO	19
even	VB	22
more	JJR	23
litigation	NN	20
.	.	17

Everyone	NN	4
by	IN	4
now	RB	2
understands	VBZ	0
that	IN	4
Congress	NNP	7
is	VBZ	5
utterly	RB	9
incapable	JJ	7
of	IN	9
writing	VBG	10
legislation	NN	11
to	TO	14
help	VB	12
deserving	JJ	16
people	NNS	14
without	IN	11
its	PRP$	19
becoming	VBG	17
some	DT	22
billion-dollar	JJ	22
morass	NN	19
.	.	4

We	PRP	2
have	VBP	0
no	DT	4
doubt	NN	2
this	DT	6
is	VBZ	4
one	CD	8
reason	NN	6
judges	NNS	14
in	IN	9
New	NNP	12
York	NNP	10
and	CC	14
justices	NNS	19
on	IN	14
the	DT	18
Supreme	NNP	18
Court	NNP	15
are	VBP	8
willing	JJ	19
to	TO	22
trash	VB	20
the	DT	24
law	NN	22
in	IN	22
the	DT	28
DES	NNP	28
cases	NNS	25
.	.	2

They	PRP	2
must	MD	0
figure	VB	2
that	IN	3
justice	NN	6
has	VBZ	4
to	TO	8
get	VB	6
done	VBN	8
by	IN	9
somebody	NN	10
,	,	3
but	CC	3
know	VB	3
it	PRP	16
wo	MD	14
n't	RB	16
be	VB	16
done	VBN	18
by	IN	19
Congress	NNP	20
.	.	2
